Thyroid disorders during interferon alpha therapy in 625 patients with chronic hepatitis C: a prospective cohort study.
Ann Endocrinol (Paris)
; 67(4): 343-7, 2006 Sep.
Article
in En
| MEDLINE
| ID: mdl-17072240
ABSTRACT
AIM:
to report the prevalence, risk factors, management and long-term outcome of thyroid disorders caused by INFalpha in patients with chronic hepatitis C. PATIENTS ANDMETHODS:
From January 1991 to December 2004, 625 patients with chronic hepatitis C underwent INFalpha therapy. TSH assay was normal and antithyroperoxidase antibodies (anti-TPO) was performed before onset antiviral treatment; then TSH was performed every 2 months in all patients during therapy, and every 3 months after treatment.RESULTS:
58 patients developed thyroid disorder (8.9%). Mean age was 50.6+/-13 years; sex ratio 1 M/2 F; the anti-TPO antibodies were positive before onset antiviral treatment in 9 patients (13.8%). 26 patients developed hypothyroidism (44.8%), 9 patients developed hyperthyroidism (15.5%) and among them 3 cases of Grave's disease. Biphasic thyroiditis occurred in 21 patients (36.2%), anti-TPO increase during treatment in 2 patients (3.5%) without hypothyroidism. The dysthyroidism was more frequent in risk in female gender (p<0.05) and in the group with positive antiTPO antibodies before treatment (p<0.02).CONCLUSION:
Female gender and positive antiTPO antibodies are the predictive factors of development of the thyroid dysfunction during INFalpha therapy.
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Thyroid Diseases
/
Interferon-alpha
/
Hepatitis C, Chronic
Type of study:
Etiology_studies
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limits:
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Ann Endocrinol (Paris)
Year:
2006
Document type:
Article
Affiliation country:
Morocco
Publication country:
FR
/
FRANCE
/
FRANCIA
/
FRANÇA